Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4544MR)

This product GTTS-WQ4544MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4544MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5282MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CD124
GTTS-WQ14987MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ13456MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRS-343
GTTS-WQ3806MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BB-10901
GTTS-WQ9630MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ11352MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-551
GTTS-WQ14986MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SHR-1314
GTTS-WQ14599MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SAR-650984
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW